Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy.

摘要: The occurrence of treatment-related hematologic malignancies after adjuvant therapy with alkylating agents for gastrointestinal cancers, ovarian carcinoma, and breast cancer treatment Hodgkin's disease, non-Hodgkin's lymphoma, germ-cell tumors, multiple myeloma has been well documented. Adjuvant chemotherapy is frequently used the early stage cancer, to date there no increase in incidence secondary myelodysplastic syndromes or acute leukemia cyclophosphamide-based regimens when compared surgical controls. This report describes two patients who developed myelocytic only exposure cyclophosphamide, methotrexate, 5-fluorouracil therapy. These cases leukemia, which 3 years diagnosis initiation chemotherapy, were characterized by trilineage dysplasia pancytopenia, had abnormalities chromosomes 5 7: characteristics consistent leukemia. Many women are diagnosed each year potential candidates Although certain subgroups have shown benefit from therapy, continued efforts must be directed at identifying responders so that others will not exposed additional risks chemotherapy.